HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $15 price target.
July 22, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Biora Therapeutics and maintained a $15 price target.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100